2. GPCR/G Protein
  3. Formyl Peptide Receptor (FPR)
  4. Annexuzlimab

Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma.

For research use only. We do not sell to patients.

Annexuzlimab

Annexuzlimab Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Annexuzlimab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

Annexin A1/ANXA1
In Vitro

Annexuzlimab (MDX-124) (2.5-10 μM; 72 h) significantly reduces proliferation in a dose-dependent manner in ANXA1-expressing human cancer cell lines, with 10 μM causing >50% viability reduction in some breast and ovarian cell lines, but has no effect on non-ANXA1-expressing lung cancer cell lines[1].
Annexuzlimab (10-25 μM; 24 h) induces a dose-dependent G1 phase cell cycle arrest, with 25 μM causing the most pronounced effects (33.5% G1 increase in MDA-MB-231, 21.2% in A549, 10.8% in BxPC-3), and does not induce apoptosis[1].
Annexuzlimab (5 μM; 72 h) does not induce apoptosis in MCF-7 breast or Caco-2 colorectal cancer cells[1].
Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell line[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Annexuzlimab Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MCF-7, HCC1806, MDA-MB-231, MCF-7/TAMR7, BxPC-3, MIA PaCa-2, PANC-1, A2780, A2780cis, A2780ADR, Caco-2, HCT116, SW480, NCI-H69/CPR, A549, COR-L23, COR-L23.5010
Concentration: 2.5-10 μM
Incubation Time: 72 h
Result: Caused a significant dose-dependent reduction in cellular proliferation in all ANXA1-expressing breast, pancreatic, ovarian, colorectal, and some lung cancer cell lines compared to IgG1 isotype control; At 10 μM, MCF-7, HCC1806, and MDA-MB-231 had >50% viability reduction, MCF-7/TAMR7 had 21% reduction, BxPC-3 had 40% reduction, MIA PaCa-2 had 20% reduction, PANC-1 had 34% reduction, A2780 had 31% reduction, A2780cis had 48% reduction, A2780ADR had 72% reduction, Caco-2, HCT116, and SW480 had significant reduction, NCI-H69/CPR had 36% reduction, A549 had 37% reduction; Showed no anti-proliferative activity in non-ANXA1-expressing COR-L23 and COR-L23.5010 lung cancer cells.

Cell Cycle Analysis[1]

Cell Line: BxPC-3, MIA PaCa-2, MDA-MB-231, A549
Concentration: 10 μM, 25 μM
Incubation Time: 24 h
Result: Induced a dose-dependent G1 phase cell cycle arrest compared to untreated control cells; At 25 mM, MDA-MB-231 had a 33.5% increase in G1 phase and 29.1% decrease in S phase, A549 had a 21.2% increase in G1 phase and 18.3% decrease in S phase, BxPC-3 had a 10.8% increase in G1 phase and 10.4% decrease in S phase; Did not induce apoptosis (no sub G0/G1 peak observed).

Apoptosis Analysis[1]

Cell Line: MCF-7, Caco-2
Concentration: 5 μM
Incubation Time: 72 h
Result: Showed no significant difference in the percentage of early or late apoptotic/necrotic cells compared to untreated control cells.
In Vivo

Annexuzlimab (1 mg/kg; i.v.; two doses on day 1 and day 8) inhibits tumour growth in BALB/c mice model of triple-negative breast cancer (with a tumour growth inhibition of 23%)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 9 weeks old, orthotopic inoculation with 4T1-luc murine triple-negative breast cancer cells)[1]
Dosage: 1 mg/kg
Administration: i.v.; two doses on day 1 and day 8
Result: Significantly inhibited tumour growth versus vehicle control, achieving 23% tumour growth inhibition by day 15. Observed no noticeable change in body weight throughout the study.
Gene ID

301  [NCBI]

Accession

P04083
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Annexuzlimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AnnexuzlimabMDX-124MDX124MDX 124Formyl Peptide Receptor (FPR)triple negative breast cancerAnnexin-A1FPR1/24T1-luc syngeneic mouse modelANXA1formyl peptide receptors 1 and 2osteosarcomaG1 phaseOS cell linesBALB/c mice modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Annexuzlimab
Cat. No.:
HY-P991864
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.